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OBJECTIVEdFetuin-A levels are associated with higher risk of type 2 diabetes, but it is
unknown if the association is causal. We investigated common (.5%) genetic variants in the
fetuin-A gene (AHSG) fetuin-A levels, fasting glucose, and risk of type 2 diabetes.
RESEARCH DESIGN AND METHODSdGenetic variation, fetuin-A levels, and fasting
glucose were assessed in 2,893 Caucasian and 542 African American community-living individ-
uals 65 years of age or older in 1992–1993.
RESULTSdCommonAHSGvariants(rs4917andrs2248690)werestronglyassociatedwithfetuin-
Ac o n c e n t r a t i o n s( P , 0.0001). In analyses of 259 incident cases of type 2 diabetes, the single
nucleotidepolymorphisms(SNPs)werenotassociatedwithdiabetesriskduringfollow-upandsimilar
nullassociationswereobservedwhen579prevalentcaseswereincluded.Asexpected,higherfetuin-A
levelswereassociatedwithhigherfastingglucoseconcentrations(1.9mg/dL[95%CI,1.2–2.7]higher
perSDinCaucasians),butMendelianrandomizationanalysesusingbothSNPsasunbiasedproxiesfor
measured fetuin-A did not support an association between genetically predicted fetuin-A levels and
fasting glucose (20.3 mg/dL [95% CI, 21.9 to 1.3] lower per SD in Caucasians). The difference
between the associations of fasting glucose with actual and genetically predicted fetuin-A level was
statistically signiﬁcant (P= 0.001). Results among the smaller sample of African Americans trended in
similar directions but were statistically insigniﬁcant.
CONCLUSIONSdCommon variants in the AHSG gene are strongly associated with plasma
fetuin-Aconcentrations,butnotwithriskoftype2diabetesorglucoseconcentrations,raisingthe
possibility that the association between fetuin-A and type 2 diabetes may not be causal.
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F
etuin-A (also known as a-Heremans-
Schmidglycoprotein)issecretedfrom
the liver and reversibly binds the in-
sulin receptor tyrosine kinase in peripheral
tissues, thereby inhibiting the insulin-
induced intracellular signal cascade and
producing peripheral insulin resistance
(1–3). Elevated fetuin-A levels have
been associated with the risk of incident
type 2 diabetes in several human popu-
lations (4,5). Recently, we also observed
an association between plasma fetuin-A
concentrations and risk of type 2 diabe-
tesinalargesampleofcommunity-living
older adults who participated in the
Cardiovascular Health Study (CHS)
and were followed for a median of 11
years (6).
Thus far, little is known about the
potentialcausalrelationbetween fetuin-A
and type 2 diabetes. In the absence of
experimental evidence that selective low-
ering of fetuin-A improves insulin sensi-
tivity and reduces risk of type 2 diabetes,
investigations that use genetic variants with
strong inﬂuence on circulating fetuin-A
levels as unconfounded proxies (i.e.,
Mendelian randomization) may shed light
on the potential causal role of fetuin-A in
type 2 diabetes.
The locus (3q27) where the gene
encoding fetuin-A (AHSG)i ss i t u a t e d
has been identiﬁed in human linkage
studies of phenotypes such as the meta-
bolic syndrome and type 2 diabetes (7,8).
These ﬁndings were followed by direct
sequencing of gene-encoding regions
andtheidentiﬁcationofninehighlycor-
related single nucleotide polymor-
phisms (SNPs) with a minor allele
frequency(MAF).5%(9).Case-control
studieshavesuggestedthatafewofthese
SNPs (rs1071592, rs4917/rs4918, and
rs2248690) are associated with type 2 di-
abetes and insulin resistance (9,10), but
noneofthesestudieshadplasmameasure-
ments of fetuin-A available to evaluate the
potential causal nature of the direct asso-
ciation between fetuin-A and type 2 dia-
betes. In general, carriers of the minor
alleles of promoter variant rs2248690
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ORIGINAL ARTICLE(T; frequency in Caucasians, ;26%) and
the tightly linked nonsynonymous amino
acid substitution variants rs4917 (T; fre-
quencyinCaucasians,;33%)andrs4918
(G;frequencyinCaucasians,;34%),have
lower levels of circulating fetuin-A com-
pared with carriers of the normal wild-
type alleles (11–14).
By incorporating information for
polymorphisms at the AHSG locus with
our previous analysis of plasma fetuin-A
in relation to risk of incident type 2 dia-
betes in the CHS (6), we aimed to address
this potential causative association.
RESEARCH DESIGN AND
METHODS
Study population
The CHS is a community-based study of
older adults designed to evaluate risk fac-
tors for development and progression of
cardiovascular disease. The study design
and protocols have been described pre-
viously(15,16).Inbrief,eligibilityrequired
65 years of age or older, expectation to re-
main in the area for 3 years after recruit-
ment,noactivecancertreatment,andthe
ability to provide consent. Between
1989 and 1990, 5,201 participants
were recruited from 4 communities us-
ing Medicare eligibility lists in each area
(Sacramento, California; Forsyth County,
North Carolina; Washington County,
Maryland;andAlleghenyCounty,Pennsyl-
vania).Anadditional687AfricanAmerican
participants were recruited in 1992–1993.
We considered the 1992–1993 visit as the
baselinestudyvisitforthisanalysis.Among
5,265 individuals who participated at this
visit, weexcluded individualswhohad not
given consent for genetic analyses, those
whose samples failed genotypic quality
control (n = 1,026), and those with insuf-
ﬁcient blood specimen for fetuin-A mea-
surement (n = 390). For analyses of
fasting glucose, we additionally excluded
those with missing glucose levels at base-
line and participants who reported using
insulin or oral hypoglycemic agents. The
sample size for these analyses was 3,438
(2,893 Caucasians and 542 African Amer-
icans). In prospective analysis of incident
type 2 diabetes, we excluded participants
with prevalent or missing information for
type 2 diabetes at baseline (n =2 3 6 )a n d
thosewithnofollow-upforincidenttype2
diabetes(n=109),resultinginastudysam-
pleof3,093participants(2,627Caucasians
and 466 African Americans).
The study was approved by the In-
vestigational Review Boards of the four
clinical sites and the Data Coordinating
Center at the University of Washington.
Measurements
Fetuin-A. Plasma was collected at the
1992–1993 study visit after participants
had fasted overnight and was stored at
2708C until 2010, when it was thawed
andmeasuredforfetuin-AusinganELISA
kit (Epitope Diagnostics, San Diego, CA).
Theassayusesatwo-site“sandwich”tech-
nique with polyclonal antibodies that
bind different epitopes of human fetuin-A.
Plasma samples were measured twice in
each participant, and results were aver-
aged. We observed coefﬁcients of varia-
tion between 3.3 and 9.1%.
Genotypes. CHS is part of the National
Heart, Lung, and Blood Institute–funded
Candidate Gene Association Resource
(CARe) study (17). DNA was collected
at baseline, and genotyping was per-
formed using a gene-centric 50K SNP ar-
ray (18). This genotyping array was
designed to capture genetic variation at
;2,000 genetic loci of relevance to a
range of cardiovascular, metabolic, and
inﬂammatory syndromes. At the time of
chip development, a multistage approach
for SNP selection was taken for the selec-
tion of SNPs within the candidate loci for
theIBCarray.Foragivenlocus,knownor
putative functional SNPs were included
ﬁrst and then additional tagging SNPs
were added to capture the known varia-
tion at the locus (with MAF .0.02 and
r
2$0.8).Prioritywasgiventononsynon-
ymous and functional variants if possible.
This chip included 13 variants at the
AHSG locus (rs12486044, rs16860926,
rs2248690, rs2518136, rs34819441,
rs35457250, rs35890379, rs4831,
rs4917, rs4918, rs6444151, rs6795506,
and rs7633550). We excluded SNPs
with MAF ,5%, leaving 7 SNPs in Cau-
casians and 9 SNPs in African Americans.
Tables showing pairwise linkage disequi-
librium (LD) as measured by D9 and r
2
are provided (Supplementary Tables 1
and 2). From the CARe project, principal
components also were generated based on
ancestry-related SNPs.
Glucose and incident type 2 diabetes.
Glucose was measured in fasting blood
samplesobtainedduringtheannualclinic
examinationsin1992–1993,1996–1997,
1998–1999, and 2005–2006 and in non-
fastingbloodsamplesin1994–1995(19).
Medication use was assessed at baseline
and annually thereafter by medication in-
ventory through 2007 (20). We classiﬁed
participants as having type 2 diabetes
if fasting glucose was $126 mg/dL,
casual glucose was $200 mg/dL, or indi-
vidualsusedinsulinororalhypoglycemic
agents.
Statistical analysis
We used means and proportions of the
demographics and type 2 diabetes risk
factors to describe the study population
according to ethnicity. We assessed the
genotype and MAF for the variants and
conducted tests for Hardy-Weinberg
equilibrium. All analyses were performed
separately for Caucasian and African
American participants. We estimated
meanfetuin-Aconcentrationacrossgeno-
types and per minor allele copy in linear
regression models adjusted for age, sex,
and ﬁeld center site. Multivariable Cox
regression models were ﬁt to evaluate the
risk of incident type 2 diabetes with
adjustment for age, sex, and ﬁeld center
site. We used Schoenfeld residuals to
evaluate proportional hazards assump-
tions and found no appreciable evidence
of violations of assumptions of propor-
tionality. To see if results were stronger
when prevalent cases of type 2 diabetes
(n = 579) were included in addition to
incident diabetes as the outcome of inter-
est, we also estimated odds ratios from
logistic regression analyses including
both prevalent and incident type 2 diabe-
tes cases. To account for multiple testing,
we used Bonferroni-corrected thresholds
for statistical signiﬁcance (P , 0.007 in
Caucasians and P , 0.006 in African
Americans).
To perform a Mendelian randomiza-
tion analysis of fetuin-A and fasting glu-
cose levels, we chose two generally
unrelated SNPs and used them as a single
instrument; rs4917, a nonsynonymous
amino acid coding variant, and the pro-
moter variant rs2248690 were strongly
associatedwithfetuin-Alevelsinourdata,
w e r en o ti ns t r o n gL D ,a n dp r e v i o u s
literature suggests strong associations or
even regulatory potential of these SNPs in
relationtofetuin-Alevels(11–14,21).We
ﬁrst explored if the two SNPs were asso-
ciated with any of the potential confound-
ers listed in Table 1, and we found no
statistically signiﬁcant associations. We
used the two-stage least-squares (ivregress
function in Stata) approach to estimate the
difference in fasting glucose per 1 SD dif-
ference in genetically predicted fetuin-A
concentrations (22). We assumed an ad-
ditive genetic model (i.e., fetuin-A con-
centration increasing linearly with each
additional minor allele of the genotypes).
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Genetically elevated fetuin-A and type 2 diabetesWecomparedthedifferencesinfastingglu-
cose per 1 SD difference from analyses us-
ing measured fetuin-A concentrations and
instrumentally predicted fetuin-A (i.e., en-
dogeneity) using the Wooldridge test.
Analyses were repeated with adjustment
for population stratiﬁcation by including
the top 10 principal components as cova-
riates. All analyses were conducted using
Stata version 11.1 (StataCorp, College Sta-
tion, TX).
RESULTSdThe majority of the partic-
ipants were Caucasian (85%) and female
(60%) (Table 1). The mean was 75 years
of age for participants of Caucasian de-
scent and 73 years of age for participants
of African American descent. The mean
fetuin-A concentration was 0.48 6 0.10 g/L
in Caucasians and 0.43 6 0.09 g/L in
African Americans, and the distributions
were approximately normal within the
study samples.
Association of ASHG SNPs with
plasma fetuin-A concentrations
Table 2 lists the frequencies of the geno-
typesandminorallelesforthegeneticvar-
iants that had MAF .5%. The MAFs
differed slightly between the Caucasian
and African American subset, and two
polymorphisms were observed with
MAF .5% in the African American sam-
ple but not in the Caucasian sample
(rs16860928 and rs6795506). The three
SNPs (rs4917, rs4918, and rs2248690)
that have been consistently associated
with fetuin-A concentrations in previous
studies were frequent in both subsamples
(MAFs .25%). Borderline signiﬁcant
deviation from Hardy-Weinberg equi-
librium was observed for rs4918 in both
subsamples (P =0 . 0 4a n d0 . 0 5f o r
Caucasians and African Americans, re-
spectively) and for rs4917 in Caucasians
(P = 0.04). Among Caucasians, all the
measured SNPs were in high LD when
based on D9 (all D9 .0.9), whereas r
2
measures were not as high for SNPs that
varied in frequency. The only SNPs in
complete LD were rs4917 with rs4918
andrs2248690withrs12486044,respec-
tively.Asexpected,theLDmeasureswere
not as high in the African Americans
(Supplementary Tables 1 and 2).
Mean plasma fetuin-A concentrations
according to genotypes are also shown in
Table2.InCaucasians,theminoralleleof
all SNPs were strongly associated with
lower fetuin-A concentrations, except
for the rs4831 variant, which was weakly
associated with slightly higher fetuin-A
concentrations in both Caucasians and
African Americans. After taking multiple
testingintoconsideration,thers4831was
not statistically signiﬁcantly associated
with fetuin-A levels. The direction of as-
sociations for the minor alleles were the
same for all SNPs in African Americans,
except for the rs2518136 variant allele,
which was associated with higher fetuin-A,
and the rs16860926 variant, which was
only observed in African Americans and
wasnotstatisticallysigniﬁcantlyassociated
with fetuin-A concentrations. Carriers of
the minor alleles for the tightly linked
rs4917 (T) and rs4918 (G) variants had
lower fetuin-A concentrations (20.07 g/L
[;13%] per minor allele in Caucasians
and 20.05 g/L [;11%] in African Amer-
icans). Carriers of the rs2248690 T allele
also had lower fetuin-A concentrations
(20.06 g/L in Caucasians and 20.04 g/L
in African Americans).
Association of ASHG SNPs with
incident type 2 diabetes
We did not detect any signiﬁcant associ-
ations between the common genetic var-
iants in AHSG and risk of type 2 diabetes
in prospective analyses of either race
(Table 3) or in analyses that included
the 579 prevalent type 2 diabetes cases
(data not shown). Rather than being asso-
ciated with alowerrisk of type2 diabetes,
as would be expected based on the direc-
tion of association observed between
the genetic variants with lower plasma
fetuin-A concentrations, the variant al-
leles tended to be associated with greater
risk of type 2 diabetes by evaluation of
the point estimates, albeit none reached
statistical signiﬁcance. The risk of type 2
diabetesperadditionalcopyofthers4917
minor allele was 1.12 (95% CI, 0.92–
1.37) in Caucasians and null in African
Americans (hazard ratio [HR] 1.01;
95% CI, 0.67–1.52). The rs2248690 var-
iant allele was associated with a HR of
1.19 (95% CI, 0.96–1.48) per minor al-
lele in Caucasians, whereas the opposite
was observed for African Americans (HR
0.64; 95% CI, 0.40–1.05). Additional
adjustment for population stratiﬁcation
did not alter these estimates appreciably
(data not shown).
AHSG SNPs and fasting glucose
We next performed Mendelian ran-
domization analyses using rs4917 and
rs2248690 as instruments and using fast-
ing glucose as the outcome for maximal
power. Each 1-SD greater measured plasma
fetuin-A concentration was associated with
1.9mg/dL(95%CI,1.2–2.7)higherglucose
concentration in Caucasians and 3.5 mg/dL
Table 1dBaseline characteristics of older adults at baseline (1992): the CHS
Caucasian
N =2 , 6 2 7
African American
N = 466
Age, years 75.1 6 5.1 73.4 6 5.8
Male (%) 1,079 (41.1) 163 (35.0)
Height, cm 164.3 6 9.5 164.1 6 9.0
BMI, kg/m
2 26.2 6 4.3 28.2 6 5.5
Waist circumference, cm 96.1 6 12.7 97.9 6 13.8
Physical activity, kcal/day 1,575 6 1,867 1,040 6 1,277
Systolic blood pressure, mmHg 135.1 6 21.1 141.9 6 22.9
Triglyceride, mg/dL 143.4 6 77.6 106.9 6 52.5
HDL, mg/dL 53.5 6 14.3 59.2 6 15.6
LDL, mg/dL 128.3 6 33.2 127.6 6 33.9
CRP, g/L 4.9 6 9.3 5.9 6 7.6
Glucose 100.5 6 13.2 98.8 6 12.5
HOMA-IR 2.7 6 1.8 3.4 6 6.1
Cystatin C, mg/L 1.11 6 0.28 1.05 6 0.40
Less than high school education (%) 560 (21.3) 201 (43.2)
Income $$25,000 (%) 1,148 (46.8) 103 (23.5)
Hypertension (%) 1,367 (52.1) 338 (72.5)
Any hypertension medication (%) 1,187 (45.2) 289 (62.0)
Current smoker (%) 235 (9.1) 72 (15.6)
Nondrinker (%) 1,309 (49.9) 289 (62.6)
Characteristics among the 3,093 participants free of type 2 diabetes at baseline. CRP, C-reactive protein;
HOMA-IR, homeostasis model assessment of insulin resistance.
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Jensen and Associates(21.1 to 8.1) higher glucose concentration
in African Americans (Table 4). In contrast,
using the two AHSG SNPs as instruments,
a 1-SD increment in genetically predicted
fetuin-A concentration was associated with
slightly lower glucose levels (20.3 mg/dL
[95% CI, 21.9 to 1.3] lower glucose
per SD in Caucasians and 21.3 mg/dL
[95% CI, 28.6 to 6.1] lower in African
Americans), although neither association
reached statistical signiﬁcance. Although
the Mendelian randomization analysis
had broad CIs, the coefﬁcients for mea-
sured and genetically predicted fetuin-A
concentrations were signiﬁcantly different
from one another in Caucasians (P =
0.0001), with a similar but not statistically
signiﬁcant trend in the smaller African
American sample (P = 0.09). Inclusion of
the top 10 principal components as cova-
riates capturing potential confounding by
population stratiﬁcation did not change
the results (data not shown).
In our previous investigation from
CHS, we reported that the association
between plasma fetuin-A and risk of type
2 diabetes was stronger in individuals
younger than 75 years of age (6). We did
notobserveanystatisticallysigniﬁcant in-
teractions between the AHSG SNPs and
age on the risk of incident diabetes (all P
forinteraction.0.4)oronfastingglucose
levels (P . 0.2). Whereas the association
of plasma fetuin-A and fasting glucose
was strongest in the participants younger
than 75 years of age, the genetically pre-
dicted fetuin-A levels were not associated
with fasting glucose irrespective of age in
this study (data not shown).
CONCLUSIONSdIn a large biracial
cohort of community-living older per-
sons, we conﬁrmed previously reported
Table 2dAHSG genotypes, MAFs (polymorphisms >5% MAF), and plasma fetuin-A concentrations according to AHSG genotype and
per variant allele
SNP Alleles* MAF P for HWE AA AB BB Per B P additive
Caucasian (N = 2,627)
rs4917 CC/Ct/tt 32.3% 0.04 0.52 6 0.002 0.46 6 0.003 0.39 6 0.005 20.07 6 0.002 6.4E-162
rs4918 CC/Cg/gg 32.3% 0.04 0.52 6 0.002 0.46 6 0.003 0.39 6 0.005 20.07 6 0.002 2.5E-162
rs2248690 AA/At/tt 24.7% 0.4 0.51 6 0.002 0.45 6 0.003 0.38 6 0.007 20.06 6 0.003 3.2E-121
rs2518136 CC/Ct/tt 48.6% 0.5 0.53 6 0.003 0.48 6 0.002 0.42 6 0.003 20.06 6 0.002 1.0E-120
rs6444151 CC/Cg/gg 10.7% 0.8 0.49 6 0.002 0.44 6 0.004 0.39 6 0.017 20.05 6 0.004 5.4E-38
rs12486044 TT/Tg/gg 24.8% 0.3 0.51 6 0.002 0.45 6 0.003 0.38 6 0.007 20.06 6 0.003 1.3E-121
rs4831 CC/Cg/gg 16.1% 0.5 0.48 6 0.002 0.49 6 0.004 0.49 6 0.011 0.01 6 0.004 0.033
African American (N =4 6 6 )
rs4917 CC/Ct/tt 26.0% 0.2 0.46 6 0.005 0.41 6 0.006 0.36 6 0.013 20.05 6 0.006 3.5E-16
rs4918 CC/Cg/gg 32.6% 0.05 0.47 6 0.005 0.41 6 0.006 0.37 6 0.010 20.05 6 0.005 1.4E-24
rs2248690 AA/At/tt 25.2% 0.9 0.45 6 0.005 0.42 6 0.006 0.37 6 0.015 20.04 6 0.006 3.3E-10
rs2518136 TT/Tc/cc 32.3% 0.6 0.41 6 0.006 0.45 6 0.006 0.49 6 0.011 0.04 6 0.006 2.0E-14
rs6444151 CC/Cg/gg 5.7% 0.7 0.44 6 0.004 0.41 6 0.012 0.34 6 0.060 20.03 6 0.012 0.010
rs12486044 TT/Tg/gg 24.5% 0.3 0.46 6 0.005 0.41 6 0.006 0.35 6 0.014 20.05 6 0.006 2.0E-17
rs16860926 TT/Tc/cc 7.8% 0.07 0.44 6 0.004 0.42 6 0.010 NA 20.01 6 0.011 0.198
rs4831 CC/Cg/gg 33.0% 0.4 0.42 6 0.006 0.44 6 0.006 0.45 6 0.012 0.02 6 0.006 0.007
rs6795506 AA/Ag/gg 6.8% 0.5 0.44 6 0.004 0.39 6 0.011 0.39 6 0.049 20.05 6 0.011 6.6E-06
Among the 3,093 participants free of type 2 diabetes at baseline. Major alleles reported in uppercase letters. Fetuin-A levels (in g/L) are adjusted for age, sex, and ﬁeld
center. Data for the following SNPs with MAF ,5% are not reported: rs34819441, rs35457250, rs35890379, and rs7633550 (and rs16860926 and rs6795506 among
Caucasians).AA,homozygousmajorallele;AB,heterozygous;B,percopyofminorallele;BB,homozygousminorallele;HWE,Hardy-Weinbergequilibrium;NA,notavailable.
Table 3dAssociation of AHSG genotypes and minor alleles with risk of type 2 diabetes
in the CHS
SNP AA AB BB Per B P additive
Caucasian
rs4917_t 1 (ref) 1.03 (0.77–1.39) 1.34 (0.88–2.05) 1.12 (0.92–1.37) 0.3
rs4918_g 1 (ref) 1.02 (0.76–1.38) 1.39 (0.91–2.11) 1.13 (0.93–1.39) 0.2
rs2248690_t 1 (ref) 1.11 (0.83–1.49) 1.56 (0.94–2.57) 1.19 (0.96–1.48) 0.1
rs2518136_t 1 (ref) 0.81 (0.59–1.13) 1.01 (0.69–1.46) 1.00 (0.82–1.22) 0.99
rs6444151_g 1 (ref) 1.04 (0.74–1.48) 1.32 (0.42–4.15) 1.07 (0.78–1.45) 0.7
rs12486044_g 1 (ref) 1.10 (0.82–1.47) 1.64 (1.01–2.68) 1.20 (0.97–1.50) 0.1
rs4831_g 1 (ref) 0.78 (0.56–1.09) 0.87 (0.36–2.13) 0.83 (0.62–1.10) 0.2
African American
rs4917_t 1 (ref) 1.06 (0.61–1.84) 0.94 (0.33–2.67) 1.01 (0.67–1.52) 0.96
rs4918_g 1 (ref) 1.30 (0.75–2.26) 1.14 (0.49–2.64) 1.13 (0.78–1.63) 0.5
rs2248690_t 1 (ref) 0.69 (0.40–1.21) 0.27 (0.04–1.97) 0.64 (0.40–1.05) 0.08
rs2518136_c 1 (ref) 1.21 (0.70–2.09) 0.81 (0.31–2.11) 1.00 (0.68–1.47) 1.0
rs6444151_g 1 (ref) 0.44 (0.14–1.40) NA 0.43 (0.14–1.36) 0.2
rs12486044_g 1 (ref) 0.83 (0.47–1.47) 1.45 (0.57–3.72) 1.02 (0.67–1.56) 0.9
rs16860926_c 1 (ref) 0.46 (0.18–1.15) NA 0.46 (0.18–1.15) 0.1
rs4831_g 1 (ref) 0.67 (0.38–1.19) 0.98 (0.44–2.15) 0.88 (0.59–1.30) 0.5
rs6795506_g 1 (ref) 1.06 (0.50–2.25) 4.70 (0.63–35.02) 1.26 (0.65–2.42) 0.5
Among the 3,093 participants free of type 2 diabetes at baseline. Adjusted for age, sex, and clinic. AA, ho-
mozygous major allele; AB, heterozygous; B, per copy of minor allele; BB, homozygous minor allele; NA, not
available; ref, referent.
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Genetically elevated fetuin-A and type 2 diabetesassociations between genetic variants in
the AHSG gene with plasma fetuin-A
concentrations and between plasma
fetuin-Aconcentrationsandbothfasting
glucose and incident diabetes. However,
usingthegeneticvariantsasinstruments
to assess the potentially causal associa-
tion of fetuin-A with fasting glucose
showed that the associations with mea-
sured and genetically predicted fetuin-A
levels differed. Thus, although we can-
not exclude a potentially small associa-
tion between genetically predicted
fetuin-A and glucose, the estimate was
statistically signiﬁcantly different from
the positive association observed be-
tween measured fetuin-A and fasting
glucose.
Thisstudyconﬁrmsreportedﬁndings
that minor alleles for the tightly linked
rs4917/rs4918 variants and rs2286490
are strongly associated with lower plasma
fetuin-A concentrations (12–14). The
rs4917 is a nonsynonymous amino acid
coding variant that likely affects the tran-
scriptionoftheAHSGprotein.Itisinper-
fect LD with rs4918, and together these
two variants capture a double nonsynon-
ymous amino acid substitution that pre-
viously has been associated with lower
serum levels of fetuin-A in vivo (11).
The promoter variant rs2248690 A allele
has previously been found to upregulate
the promotor activity, resulting in higher
fetuin-A levels compared with the T allele
(21). The minor T variant may change a
transcriptionbindingsiteforaco-repressor,
leading to lower expression of the AHSG
protein and thus signiﬁcantly lower
fetuin-A levels.
We also found similar associations
for the other commonly occurring var-
iants across the AHSG gene, indicating a
genetic region with a high extent of LD,
especially in Caucasians.
We (6) and others (4,5) previously
have reported that higher plasma fetuin-A
concentrations are associated with greater
risk of type 2 diabetes. Here, we extend
these ﬁndingsbyreporting that SNPsasso-
ciated with lower fetuin-A concentrations
were not associated with a lower risk of
type 2 diabetes or fasting glucose concen-
trations, suggesting that genetically ele-
vated fetuin-A may not be causally related
to type 2 diabetes.
Other studies also have explored
candidate SNPs in AHSG in relation to
type 2 diabetes and markers of insulin
sensitivity with conﬂicting results. In a
case-control study, the rs1071592 minor
allele was statistically signiﬁcantly less
prevalent among individuals with type 2
diabetes compared with normoglycemic
controls (9). Minor alleles at rs4918 and
rs2248690 showed the same tendencies,
although associations did not reach sta-
tistical signiﬁcance. Surprisingly, no
association was observed for rs4917 de-
spite its being in near complete LD with
rs4918 (9). None of the investigated
AHSG SNPs were associated with ho-
meostasis model assessment of insulin
resistance or glucose levels in the ;700
normoglycemic controls (9). In a Danish
study of .7,000 healthy participants,
the ﬁnding of an association with risk
of type 2 diabetes was not replicated for
the rs1071592 variant; rs4917/rs4918
exhibited lower insulin resistance and
fasting insulin but were not associated
with risk of type 2 diabetes (10).
There are a number of possible rea-
sons for the disparity in the associations
of plasma fetuin-A concentrations and
fetuin-A–associated SNPs with fasting
glucose concentrations and risk of type
2 diabetes. One possibility is that the ob-
served association between elevated
plasma fetuin-A concentrations and risk
of type 2 diabetes is confounded by other
determinants of fetuin-A concentrations,
whereas the fetuin-A genotype is not
subject to confounding by similar factors.
For example, fetuin-A, which is derived
from hepatocytes, appears to increase
with hepatic steatosis and obesity, which
themselves have been independently
associated with risk of type 2 diabetes
(23–25). Importantly, the AHSG SNPs
donotappeartobeassociatedwithother
glucose-related traits available in CHS,
and the locus has not been implicated
in nonalcoholic fatty liver disease. This
suggests that these AHSG SNPs meet the
necessary criteria for Mendelian randomi-
zation analyses of not being associated
with potential confounders and not in-
ﬂuencing the outcome through another
potential intermediate. Although using
genetic markers as instrumental variants
for fetuin-A level is limited by the degree
to which genetics contribute to the inter-
individual variation in circulating fetuin-A
levels(26),ourCIs(whichreﬂecttheother
sources of variability) excluded large ef-
fects of genetically determined fetuin-A
on glucose.
It is also possible that the differences
between the relationships of measured
plasma fetuin-A concentrations and the
fetuin-A genotype with fasting glucose
concentrations and risk of type2 diabetes
relate to our study of older community-
living individuals. Participants in this
study had an average of 75 years of age
atblooddraw;therefore,wemaynothave
captured the appropriate study popula-
tion if the studied genetic variants impact
risk of type 2 diabetes primarily earlier in
life. Two variants (the rs4917/rs4918
polymorphisms) were slightly out of
Hardy-Weinberg equilibrium, which
might indicate an unlikely scenario of
survival bias. We found no similar issues
for the remainder of the variants.
Another explanation may be related
to the fact that individuals who carry the
major AHSG allelic variants, and thus
have lived with elevated fetuin-A levels
into older age, may have developed com-
pensatory mechanisms that buffer against
Table 4dDifferences in fasting glucose per 1 SD difference in fetuin-A and per 1 SD
difference in genetically predicted fetuin-A
Caucasian P African American P
Measured fetuin-A n =2 , 8 0 7 n =5 3 1
Adjusted for age, sex, clinic 2.34 (1.57–3.10) ,0.001 3.67 (20.65 to 7.99) 0.10
Fully adjusted* 1.92 (1.16–2.68) ,0.001 3.49 (21.13 to 8.12) 0.14
Genetically predicted fetuin-A n =2 , 8 9 3 n = 542
rs2248690 20.30 (22.14 to 1.53) 0.75 25.54 (216.53 to 5.45) 0.32
rs4917 20.27 (21.92 to 1.38) 0.74 0.32 (27.53 to 8.18) 0.94
Both variants 20.29 (21.91 to 1.32) 0.72 21.28 (28.62 to 6.06) 0.73
Fetuin-Awasmeasuredbyordinaryleast-squareregression,andgeneticallypredictedfetuin-Awasmeasured
by two-stage least-square regression. All analyses were adjusted for age, race, and clinic. Participants using
insulin or oral hypoglycemics were excluded. Sample size for linear regression of measured fetuin-A and
glucose was further restricted to participants with full information on covariates in the fully adjusted model.
Pfordifferencebetweentheestimatesofmeasuredfetuin-Aandgeneticallypredictedfetuin-A(basedonboth
SNPs) was 0.0001 for Caucasians and was 0.09 for African Americans (Wooldridge test). *Fully adjusted
analysis includes the following potential confounders of the association between fetuin-A and glucose levels:
physical activity, smoking, alcohol use, estimated glomerular ﬁltration rate, and prevalent cardiovascular
disease.
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Jensen and Associatesthe diabetes risk associated with higher
plasma fetuin-A concentrations. It is pos-
sible that it would take years to develop
feedback mechanisms that dampen the
effect of continuously elevated fetuin-A
concentrations on the insulin receptor,
blunting an association between the stud-
ied genetic variants and type 2 diabetes in
an elderly population used in the CHS.
We did not ﬁnd any evidence of effect
modiﬁcation when we stratiﬁed by youn-
ger than 75 years of age compared with
older than 75 years of age to explore the
associations of the genetic variants with
glucose and diabetes. However, to test
this hypothesis formally, a study popula-
tion with a larger distribution in age
would be necessary.
Inconclusion,weobservedthatgenetic
variants in the gene encoding fetuin-A
were strongly associated with lower
plasma fetuin-A concentrations but were
not associated with fasting plasma glu-
cose concentrations, prevalent diabetes,
or incident diabetes in community-living
older persons. Future studies are needed
to identify nongenetic determinants of
plasma fetuin-A concentrations and to
evaluateifsuchfactorsmayconfoundthe
association of plasma fetuin-A concen-
trations and diabetes risk.
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